Regeneron Pharmaceuticals, Inc. Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Jul-26Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Regeneron is a public company with a founder-anchored governance structure. It maintains two share classes, Class A stock carrying ten votes and common stock carrying one, with the Class A held largely by long-tenured insiders including co-founders Leonard Schleifer and George Yancopoulos. This gives the founders voting influence out of proportion to their economics, though the Class A block has shrunk over time as shares convert on transfer, and the founders do not command an outright majority of the vote.Economically, ownership is dispersed. Institutions own more than 85 percent of the common stock, with Vanguard, BlackRock, State Street and Fidelity among the largest holders, while Schleifer holds close to 4 percent and Yancopoulos a low single-digit percentage. Sanofi, which acquired nearly a quarter of the company in 2007, largely exited through a 2020 secondary offering and Regeneron repurchase, returning shares to the public float.For investors the structure is a balance. Founder voting influence supports a patient, research-led strategy and aligns two scientific leaders who built the company, while the large institutional base provides real oversight, expressed through proxy votes on matters such as executive compensation. The governance model has drawn criticism over pay, but Regeneron defends it by pointing to its record of internally discovered blockbusters.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Regeneron shareholder base combines a founder-anchored voting bloc with broad institutional ownership. Institutions hold most of the common stock, led by Vanguard, BlackRock, State Street and Fidelity, and their positions reflect the company membership in the major indices and its standing as a large-cap biotechnology holding.Active investors own Regeneron for its research engine and its four blockbuster franchises. In 2025 total revenue reached 14.3 billion dollars, up 1 percent, with net income near 4.5 billion dollars, as growth in Eylea HD, Dupixent and Libtayo offset the decline of the original Eylea under competitive pressure. Dupixent global sales, recorded by Sanofi, reached 17.8 billion dollars, and Regeneron collaboration profit share rose accordingly.Governance gives the founders disproportionate votes, so institutional influence is expressed through engagement and proxy voting rather than control. Shareholders have periodically pressed on executive compensation, but the company scientific productivity and its history of returning capital through buybacks have retained a supportive base. The key debate is whether the pipeline can offset competitive threats to the retina franchise.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|
Portfolio Analysis
Regeneron rests on four blockbuster franchises anchored by its antibody and genetics platforms. Eylea, and increasingly the higher-dose Eylea HD, treats retinal diseases and long served as the company revenue base, though the original formulation faces competition from Roche Vabysmo and lower-priced alternatives, making the transition to Eylea HD a strategic priority.Dupixent is the company most valuable franchise, an immunology drug for asthma, eczema and a widening set of inflammatory conditions, commercialized with Sanofi and used by more than a million patients worldwide. Regeneron records its share of Dupixent profits rather than the full sales, and the drug continued to grow strongly in 2025. Libtayo, an immuno-oncology therapy for skin cancers, rounds out the core along with Praluent and the rare-disease drug Evkeeza.Brand strategy flows from internal science. Regeneron discovered nearly all of its major products in house using its antibody and genetics technologies, and its pipeline spans ophthalmology, immunology, oncology and rare diseases. The company is betting that this research productivity will yield the next generation of franchises as its earliest products mature.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|
Competitive Analysis
Regeneron competes as a research-driven biotechnology company with leadership in retina, immunology and oncology. With 2025 revenue of 14.3 billion dollars, it is smaller than diversified giants like Roche and Novartis but holds commanding positions in specific markets, notably eye disease and, through Dupixent, type 2 inflammation.The sharpest competitive threat is in retina, where Roche Vabysmo and lower-cost compounded alternatives have pressured the original Eylea, driving the strategic push toward the longer-acting Eylea HD. In immunology, Dupixent faces a widening field of competitors, though its broad label and first-mover advantage have kept it dominant, with more than 1.4 million patients treated.Regeneron competitive edge is its discovery platform, which has produced a rare string of internally originated blockbusters and a deep late-stage pipeline. The risks are concentration in a few products and competitive erosion of the retina base, but the company answer is continual innovation, reinforced by its genetics investments, aimed at generating the next wave of differentiated medicines.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|
Acquisitions Analysis
Regeneron has historically grown through internal discovery rather than acquisitions, a defining trait that sets it apart from many large biotechnology peers. Its central external relationship is not an acquisition at all but its longstanding Sanofi collaboration, which shares the development and economics of Dupixent, Libtayo and other antibodies.When Regeneron does acquire, it targets specific technologies and assets rather than scale. Recent examples include the 2022 purchase of Checkmate Pharmaceuticals, the 2023 acquisition of the hearing-loss gene-therapy company Decibel, and the 2024 purchase of 2seventy bio oncology and cell-therapy assets. In 2025 it added the ophthalmology company Oxular and, notably, acquired genetic data and consumer testing assets from the bankrupt 23andMe for roughly 256 million dollars.The 23andMe purchase is strategically distinctive, extending Regeneron longstanding investment in human genetics as a discovery tool. The overall pattern is disciplined and platform-oriented, using targeted deals to reinforce internal research rather than to buy commercial revenue, a philosophy consistent with the company science-first identity.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Regeneron structural history is unusual for a large biotechnology company in how little it relies on mergers. Founded in 1988 and public since 1991, it grew primarily through internal research rather than consolidation, and it has never pursued a transformational merger of equals.The most consequential external event was its relationship with Sanofi. Beginning in 2007, Sanofi built both a deep drug-development collaboration and an equity stake approaching a quarter of the company, providing capital and partnership. In 2020 Sanofi largely exited its equity position through a secondary offering paired with a Regeneron share repurchase, a structural shift that returned billions of dollars of stock to the public float and the company treasury.Beyond Sanofi, Regeneron structural evolution has come through small, targeted acquisitions that added technologies rather than scale. This restraint reflects a deliberate identity as a science-led company that prefers to build its franchises internally rather than acquire them.
Ownership History
Ownership History Analysis
Regeneron was founded in 1988 by physician-scientist Leonard Schleifer, who was joined the following year by the scientist George Yancopoulos, beginning a partnership that has defined the company for more than three decades. The pair built Regeneron on a conviction that rigorous internal science, rather than in-licensing, would yield differentiated medicines.After years of research investment, the company breakthrough came with Eylea in retinal disease and then Dupixent in immunology, developed with Sanofi, which together transformed Regeneron into a highly profitable biotechnology leader. Its antibody and genetics platforms produced a rare succession of internally discovered blockbusters.Today Regeneron is led by its founders, Schleifer as chief executive and Yancopoulos as chief scientific officer, both serving as board co-chairs, with 2025 revenue of 14.3 billion dollars. Its history is one of patient, science-first company building, sustained by a governance structure that has allowed the founders to steer a long-term research strategy.
Ownership Explained
Regeneron is a publicly traded biotechnology company whose founders retain outsized voting influence through a dual-class structure. Co-founders Leonard Schleifer, the chief executive, and George Yancopoulos, the chief scientific officer, serve as board co-chairs and hold Class A shares carrying ten votes each. Their economic stakes are meaningful yet under ten percent combined, while institutions led by Vanguard and BlackRock own most of the common stock. Sanofi, once a large holder, largely exited in 2020.
The dual-class structure lets Regeneron founders steer a long-horizon, science-first strategy without fear of activists or takeovers, even though they own a minority of the economics. Institutional holders own the bulk of the value but carry less voting weight, a trade many accept given the company research record. The founders scientific leadership keeps strategy anchored in internal drug discovery. Concentrated voting has drawn governance scrutiny, particularly over executive pay.